Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Cambridge NeuroScience/Gladstone Institute AD collaboration

Jan. 3, 1997

German investigators present potent dopamine D1 antagonist

Jan. 3, 1997

Nippon Zoki claims aFGF fragments for CNS indications

Jan. 3, 1997

Debate centers on the safety of coated aspirin

Jan. 2, 1997

Antidementia agents reported by Eisai

Jan. 2, 1997

Novel anticonvulsant approved by FDA

Dec. 31, 1996

Japanese researchers describe analgesic tripeptides

Dec. 31, 1996

First phase II results for Innapharma's peptide antidepressant

Dec. 30, 1996

New agents for CNS disorders claimed by HHS

Dec. 30, 1996

Copaxone approved by FDA

Dec. 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...